ライフサイエンスコーパス: zoledronic acid

1 ncer patients (ibandronate, pamidronate, and zoledronic acid).

2 patients received open-label treatment with zoledronic acid.

3 tically, with comparable efficacy to that of zoledronic acid.

4 c and vascular cell lineages challenged with zoledronic acid.

5 vant systemic therapy either with or without zoledronic acid.

6 f CXCR4 was abrogated with the OC inhibitor, zoledronic acid.

7 ation in both cell lines upon challenge with zoledronic acid.

8 he utility of the intravenous bisphosphonate zoledronic acid.

9 of the osteogenic vasculature in response to zoledronic acid.

10 d osteoclastogenesis, which was prevented by Zoledronic acid.

11 d predict the treatment outcomes of adjuvant zoledronic acid.

12 status and menopausal status on efficacy of zoledronic acid.

13 al small GTPases and this was potentiated by zoledronic acid.

14 CLP-induced bone loss was prevented by Zoledronic acid.

15 benefit with the addition of pravastatin and zoledronic acid.

16 mbinations with lonafarnib, pravastatin, and zoledronic acid.

17 othesis that ibandronic acid was inferior to zoledronic acid.

18 o evidence of a benefit from the addition of zoledronic acid (0.94 [0.83-1.07]; p=0.323), which trans

19 sphosphonates (1.03 [0.89-1.18]; p=0.724) or zoledronic acid (0.98 [0.82-1.16]; p=0.782).

20 The effects of zoledronic acid (1-100 uM), Histatin-1 (10 uM), or their

21 travenous placebo (n = 1,026) or intravenous zoledronic acid 4 mg adjusted for creatinine clearance a

22 ate 90 mg delivered over at least 2 hours or zoledronic acid 4 mg delivered over at least 15 minutes

23 idronate 90 mg over no less than 2 hours, or zoledronic acid 4 mg over no less than 15 minutes every

24 n automated telephone service to intravenous zoledronic acid (4 mg every 21-28 days) or oral clodroni

25 Zoledronic acid (4 mg infused over 15 minutes) is the fi

26 y assigned in a blinded 1:1 ratio to receive zoledronic acid (4 mg intravenously every 4 weeks) or a

27 ations It is recommended that, if available, zoledronic acid (4 mg intravenously every 6 months) or c

28 d to receive either upfront or delayed-start zoledronic acid (4 mg intravenously every 6 months).

29 res more than -2.5 were randomly assigned to zoledronic acid (4 mg intravenously on day 1 only) or pl

30 Zoledronic acid (4 mg) was given for six 3-weekly cycles

31 Patients were randomly assigned to receive zoledronic acid (4 or 8 mg) or placebo every 3 weeks for

32 90 mg intravenously, every 3 to 4 weeks; or zoledronic acid, 4 mg intravenously every 12 weeks or ev

33 ed to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive

34 of age to receive an intravenous infusion of zoledronic acid (5 mg) or placebo at baseline and at 12

35 randomized to receive infusions with either zoledronic acid (5 mg) or placebo, administered at basel

36 ed in 40 female Sprague Dawley rats received zoledronic acid (7.5 ug/kg) plus dexamethasone (1 mg/kg)

37 Osteoclast inhibition with zoledronic acid (a bisphosphonate) or with denosumab (a

38 The drug zoledronic acid, a bisphosphonate given for prevention o

39 antitumoral and antiosteolytic activities of zoledronic acid, a bisphosphonate inhibitor of osteoclas

40 These data suggest that zoledronic acid, a drug already in clinical use, may be

41 ring peripheral blood mononuclear cells with zoledronic acid, a gammadelta T lymphocyte activating ag

42 pletion enhanced it, even in the presence of zoledronic acid, a potent antiresorptive agent.

43 Zoledronic acid, a potent bisphosphonate, is commonly ad

44 Zoledronic acid, a potent inhibitor of osteoclast activi

45 Zoledronic acid, a third-generation aminobisphosphonate,

46 To determine whether zoledronic acid administered every 12 weeks is noninferi

47 dministered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks.

48 Patients were randomized to receive zoledronic acid administered intravenously every 4 weeks

49 Zoledronic acid administered with chemotherapy resulted

50 resistance when compared with treatment with zoledronic acid alone.

51 Zoledronic acid also significantly improved progression-

52 ated for more than 3 months (272 patients on zoledronic acid and 273 on risedronate), and the prevent

53 is enhanced by aminobisphosphonates such as zoledronic acid and alendronic acid, both of which promo

54 celecoxib, zoledronic acid and docetaxel, or zoledronic acid and celecoxib) improves survival in men

55 nse did not differ significantly between the zoledronic acid and clodronic acid groups for patients r

56 l (SOC + Doc), or standard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc).

57 rugs (docetaxel, zoledronic acid, celecoxib, zoledronic acid and docetaxel, or zoledronic acid and ce

58 animals were treated with the bisphosphonate zoledronic acid and imaged with (64)Cu-RGD to determine

59 predict likelihood of benefit from adjuvant zoledronic acid and merits further investigation as a po

60 The zoledronic acid and placebo groups did not differ signif

61 group 2 with intravenous drug application of zoledronic acid and test group 3 with a subcutaneous app

62 These agents are the bisphosphonate zoledronic acid and the monoclonal antibody denosumab.

63 wo osteoclast inhibitors, the bisphosphonate zoledronic acid and the RANKL inhibitor osteoprotegerin,

64 rol group) and thrombosis (five of 60 in the zoledronic acid and two of 59 in the control group).

65 The proapoptotic effect of zoledronic acid and zoledronic acid in combination with

66 iously received a standard dosing regimen of zoledronic acid and/or pamidronate disodium.

67 r who previously received 9 or more doses of zoledronic acid and/or pamidronate during the first 10 t

68 fter treatment with the osteoclast inhibitor zoledronic acid, and histologic analysis of Tax(+) mouse

69 ford progeria syndrome received pravastatin, zoledronic acid, and lonafarnib.

70 acted cytotoxic and antimigratory effects of zoledronic acid, and restored the angiogenic capacity in

71 Moreover, agents targeting bone biology (eg, zoledronic acid, anti-DKK-1 MoAb, anti-B-cell activating

72 te, intravenous pamidronate, and intravenous zoledronic acid are superior to placebo in reducing skel

73 automated telephone service, to receive 4 mg zoledronic acid as an infusion every 3-4 weeks or 1600 m

74 6 weeks of treatment with either intravenous zoledronic acid at 4 mg every 3-4 weeks or oral ibandron

75 were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients w

76 4 bisphosphonate-treated patients-1,462 with zoledronic acid (breast, 490; prostate, 411; myeloma, 21

77 ditional use of one or two drugs (docetaxel, zoledronic acid, celecoxib, zoledronic acid and docetaxe

78 Treatment with anti-sclerostin antibody and zoledronic acid combined increased bone mass and fractur

79 ist bones with erosions was 0.3 +/- 0.75 for zoledronic acid compared with 1.4 +/- 1.77 for placebo (

80 s study was to assess whether treatment with zoledronic acid, compared with placebo, could achieve a

81 The combination of zoledronic acid + cyclophosphamide/topotecan also signif

82 Zoledronic acid decreased cell viability and migration o

83 A single infusion of intravenous zoledronic acid decreases bone turnover and improves bon

84 Zoledronic acid decreases the risk for skeletal-related

85 Combinations of pitavastatin with zoledronic acid displayed additive or synergistic effect

86 research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to stan

87 However, zoledronic acid does reduce the development of bone meta

88 ined after discontinuation of alendronate or zoledronic acid, drug holidays after 5 years of alendron

89 A once-yearly infusion of zoledronic acid during a 3-year period significantly red

90 onate, etidronate, ibandronate, risedronate, zoledronic acid, estrogen, parathyroid hormone (1-34), a

91 3 were white [86.5%]), 203 patients received zoledronic acid every 12 weeks (mean [SD] age, 58.6 [11.

92 tate cancer, or multiple myeloma, the use of zoledronic acid every 12 weeks compared with the standar

93 4 weeks group and 47 patients (23.2%) in the zoledronic acid every 12 weeks group (proportional diffe

94 To examine whether zoledronic acid every 12 weeks was noninferior to zoledr

95 els were higher) among patients who received zoledronic acid every 12 weeks.

96 one (control group) or with 4 mg intravenous zoledronic acid every 3-4 weeks for six doses, then ever

97 stemic therapy alone (control group) or with zoledronic acid every 3-4 weeks for six doses, then ever

98 mized (1:1) to receive 4.0 mg of intravenous zoledronic acid every 4 or every 12 weeks with placebo f

99 women were randomized: 200 patients received zoledronic acid every 4 weeks (mean [SD] age, 59.2 [11.1

100 SREs occurred in 44 patients (22.0%) in the zoledronic acid every 4 weeks group and 47 patients (23.

101 ronic acid every 12 weeks was noninferior to zoledronic acid every 4 weeks in patients with metastati

102 A total of 260 patients (29.5%) in the zoledronic acid every 4-week dosing group and 253 patien

103 or genomic profiling is possible, but use of zoledronic acid for more than 1 year may reduce the yiel

104 mpling, lesion size, core number, and use of zoledronic acid for more than 1 year.

105 mpared oral ibandronic acid with intravenous zoledronic acid for the treatment of metastatic breast c

106 We first show that zoledronic acid given at the same time (early prevention

107 Zoledronic acid given by intravenous infusion has been w

108 [HR] 0.92, 95% CI 0.59-1.41), but was in the zoledronic acid group (0.52, 0.36-0.75).

109 h 26 confirmed on central review, all in the zoledronic acid group (1.7%, 95% CI 1.0-2.4).

110 for intention-to-treat analysis: 981 in the zoledronic acid group (555 on intensive chemotherapy, 42

111 safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in

112 ian time to first SRE was 31.9 months in the zoledronic acid group (95% CI, 24.2 to 40.3) and 29.8 mo

113 ups: 493 in the control group and 473 in the zoledronic acid group (adjusted hazard ratio [HR] 0.94,

114 fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001).

115 ction of 28% in deaths from any cause in the zoledronic acid group (P=0.01).

116 f any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a

117 The numbers of deaths--243 in the zoledronic acid group and 276 in the control group--were

118 Cs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the contr

119 nce or death occurred in 377 patients in the zoledronic acid group and 375 of those in the control gr

120 phometric vertebral fracture was 1.6% in the zoledronic acid group and 4.9% in the placebo group over

121 in rates of overall survival of 85.4% in the zoledronic acid group and 83.1% in the control group (ad

122 e randomly assigned and analysed--981 in the zoledronic acid group and 979 in the clodronic acid grou

123 s were infection (five of 60 patients in the zoledronic acid group and six of 59 in the control group

124 was not significantly different between the zoledronic acid group and the placebo group over 24 mont

125 hand and wrist erosions was 61% lower in the zoledronic acid group compared with the placebo group (0

126 ized bone edema developed was smaller in the zoledronic acid group compared with the placebo group (3

127 of 3.7 years (IQR 2.9-4.7), patients in the zoledronic acid group had a lower incidence of skeletal-

128 The zoledronic acid group had a mean change in the number of

129 More patients in the zoledronic acid group had renal toxic effects than in th

130 Fewer patients in the zoledronic acid group had vertebral fractures than did t

131 essed by a visual analog scale (-11.5 in the zoledronic acid group vs -16.8 in the placebo group; bet

132 in the clodronic acid group (50 [5%] in the zoledronic acid group vs 88 [9%] in the clodronic acid g

133 tive (85 in the control groups and 99 in the zoledronic acid group) and the remaining tumours were MA

134 es (445 in the control groups and 420 in the zoledronic acid group).

135 in each group (adjusted hazard ratio in the zoledronic acid group, 0.98; 95% confidence interval [CI

136 In the zoledronic acid group, bone marrow was not collected fro

137 In the zoledronic acid group, there were 17 confirmed cases of

138 in the ibandronic acid group and 672 in the zoledronic acid group.

139 one documented case of osteonecrosis in the zoledronic acid group.

140 eriod, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; re

141 the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; haz

142 e proportion with an SRE was reduced in both zoledronic acid groups compared with the placebo group (

143 Fewer participants who received zoledronic acid had clinical vertebral or nonvertebral f

144 versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs (p=0.054).

145 h men who received placebo, men who received zoledronic acid had fewer moderate-to-severe vertebral f

146 Zoledronic acid has not been studied in patients with se

147 Intravenous zoledronic acid has recently been shown to be as effecti

148 in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects i

149 ion of skeletal-related events, showing that zoledronic acid has treatment benefits beyond bone healt

150 ls; however, its effects on cells exposed to zoledronic acid have not been explored.

151 In recent years, bisphosphonates such as zoledronic acid have shown efficacy in preventing and de

152 AEs and acute-phase reactions occurred with zoledronic acid; hypocalcemia occurred more frequently w

153 Pitavastatin (IC50 = 0.6-14 muM), zoledronic acid (IC50 = 21-57 muM), risedronate (IC50 >

154 However, zoledronic acid improved IDFS in those who were over 5 y

155 No evidence exists to suggest that zoledronic acid improves survival in men with M1 or M0 d

156 2004 until 2007 followed by two infusions of Zoledronic acid in 2008 and 2009.

157 Intravenous infusion with either 5 mg of zoledronic acid in a 100-mL saline solution (n = 113) or

158 e proapoptotic effect of zoledronic acid and zoledronic acid in combination with 4-HC on tumor cells

159 active against tumor cells and suggest that zoledronic acid in combination with cytotoxic chemothera

160 f nuclear factor kappa B (RANK) ligand, with zoledronic acid in delaying or preventing skeletal-relat

161 Denosumab was superior to zoledronic acid in delaying or preventing SREs in patien

162 Denosumab was superior to zoledronic acid in delaying time to first on-study SRE (

163 l recommends only intravenous pamidronate or zoledronic acid in light of the use of the time to first

164 fficacy and safety of earlier treatment with zoledronic acid in men with castration-sensitive metasta

165 s the cytotoxic and antimigratory effects of zoledronic acid in osteoblast-like and endothelial cells

166 se findings support immediate treatment with zoledronic acid in patients with newly diagnosed multipl

167 e findings do not support the routine use of zoledronic acid in the adjuvant management of breast can

168 sumab, a RANK-ligand antagonist, compared to zoledronic acid in the prevention of skeletal related ev

169 These findings do not support the use of zoledronic acid in the treatment of knee osteoarthritis.

170 The data indicate that zoledronic acid, in addition to inhibiting osteoclasts,

171 a study to determine whether treatment with zoledronic acid, in addition to standard adjuvant therap

172 Annual zoledronic acid increases BMD in postmenopausal women, b

173 herapy to develop orbital inflammation after Zoledronic acid infusion.

174 teoarthritis and bone marrow lesions, yearly zoledronic acid infusions, compared with placebo, did no

175 following extraction of healthy teeth after zoledronic acid infusions.

176 In vitro, zoledronic acid inhibited neuroblastoma cell proliferati

177 Zoledronic acid inhibited the association of Ras with th

178 sing allocation concealment, to receive 4 mg zoledronic acid intravenously every 3 weeks (n=60), or n

179 Intravenous use of pamidronate and zoledronic acid is associated with most cases.

180 A single 5 mg intravenous infusion of zoledronic acid is non-inferior, possibly more effective

181 Our results suggest that zoledronic acid is preferable to ibandronic acid in prev

182 The optimal dosing interval for zoledronic acid is uncertain.

183 on reduced radiographic vertebral fractures (zoledronic acid; low SOE) and clinical vertebral fractur

184 Annual zoledronic acid may be a convenient and effective strate

185 ypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs.

186 is less clear, but recent data suggest that zoledronic acid may modify the course of the disease and

187 f-principle study suggested that intravenous zoledronic acid may reduce knee pain and the size of bon

188 (HMG)-CoA reductase and the N-bisphosphonate zoledronic acid monohydrate, an inhibitor of protein pre

189 ction in risk of skeletal complications with zoledronic acid must be weighed against potential advers

190 833 patients were randomised 1:1 to receive zoledronic acid (n=416) or risedronate (n=417).

191 id intravenously every 3 weeks (n=60), or no zoledronic acid (n=60), for 1 year concomitant with four

192 aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cell

193 The effects of zoledronic acid on DFS were not affected by oestrogen-re

194 nvestigate the effect of the adjuvant use of zoledronic acid on disease-free survival (DFS) in high-r

195 We studied the effect of zoledronic acid on fracture risk among men with osteopor

196 assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period.

197 controlled trial to evaluate the effects of zoledronic acid on time to first bone metastasis in men

198 e Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture T

199 Most studies evaluated zoledronic acid or clodronate, and data are extremely li

200 intravenous ibandronate), or have completed (zoledronic acid) or are currently in (denosumab) phase I

201 intravenous ibandronate), or have completed (zoledronic acid) or are currently in (denosumab) phase I

202 gic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip

203 nt with the potential anticancer activity of zoledronic acid, overall survival improved independently

204 ncreased by 4.0% +/- 1.0% in men assigned to zoledronic acid (P < .001).

205 ncreased by 0.7% +/- 0.5% in men assigned to zoledronic acid (P = .004).

206 r markers were lower in the men who received zoledronic acid (P<0.05 for both comparisons).

207 the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new

208 ccurred infrequently (2.0%, denosumab; 1.4%, zoledronic acid; P = .39).

209 -existing renal impairment were added to the zoledronic acid package insert.

210 Use of zoledronic acid, peripheral sampling, core number, and l

211 results in structural end points in favor of zoledronic acid plus MTX compared with MTX alone.

212 for which he was receiving intravenous (IV) zoledronic acid, presented for routine periodontal maint

213 se, osteoclast inhibition with bone-targeted zoledronic acid protected Tax+ mice from bone and soft-t

214 However, liposomal zoledronic acid proved highly toxic to SCID Beige mice.

215 sults of this study support the early use of zoledronic acid rather than clodronic acid in patients w

216 months after the intravenous bisphosphonate zoledronic acid received regulatory approval for marketi

217 with osteopenia or osteoporosis, 6 years of zoledronic acid reduced clinical fractures (HR, 0.73 [CI

218 Zoledronic acid reduced mortality by 16% (95% CI 4-26) v

219 Zoledronic acid reduced the development of bone metastas

220 Treatment with zoledronic acid reduced the risk of morphometric vertebr

221 h bone metastases recently demonstrated that zoledronic acid reduces the risk of skeletal-related eve

222 riod, representing a 67% risk reduction with zoledronic acid (relative risk, 0.33; 95% confidence int

223 evaluated combinations of pitavastatin with zoledronic acid, risedronate and GGTI-2133 in a panel of

224 Zoledronic acid showed no evidence of survival improveme

225 treatment combinations with pravastatin and zoledronic acid significantly improved bone structure an

226 ving a GnRH agonist, a single treatment with zoledronic acid significantly increased BMD and durably

227 Additionally, 4 mg zoledronic acid significantly increased time to first ev

228 y (SOC-only; control), standard of care plus zoledronic acid (SOC + ZA), standard of care plus doceta

229 events were more frequent in patients given zoledronic acid than in those on risedronate, largely as

230 Adverse events were more common with zoledronic acid than with placebo (96% vs 83%, respectiv

231 Zoledronic acid, the most frequent agent associated with

232 risons between clodronate and pamidronate or zoledronic acid, the superiority of one agent cannot be

233 ibandronic acid and 0.435 (0.393-0.480) with zoledronic acid; the rate ratio for skeletal-related eve

234 Long-term alendronate and zoledronic acid therapies reduce fracture risk in women

235 suggest a structural benefit associated with zoledronic acid therapy in patients with RA, as demonstr

236 5 years of alendronate therapy or 3 years of zoledronic acid therapy may be considered for patients a

237 Synergy Trial (Z-FAST) indicate that upfront zoledronic acid therapy prevents bone loss in the LS in

238 dexamethasone (RVD) plus monthly intravenous zoledronic acid therapy.

239 o receive ibandronic acid and 699 to receive zoledronic acid; three patients withdrew immediately aft

240 The addition of zoledronic acid to adjuvant letrozole therapy may protec

241 l-QoL) in a large randomized trial (Adjuvant Zoledronic Acid to Reduce Recurrence [AZURE]).

242 gest no overall benefit from the addition of zoledronic acid to standard adjuvant treatments for earl

243 lows: OVX (n = 5): OVX plus saline solution; zoledronic acid-treated group (ZOL) (n = 6): OVX plus ZO

244 d osteoclast surface area in antibiotic- and zoledronic acid-treated mice as compared with convention

245 aseline characteristics were similar in both zoledronic acid treatment arms.

246 Zoledronic acid treatment was associated with a signific

247 last activity, decreased significantly after zoledronic acid treatment.

248 e FIT trial, 1.50 (95% CI, 0.25 to 9.00) for zoledronic acid use in the HORIZON-PFT trial, and 1.33 (

249 acebo group (38% for 4 mg and 35% for 8/4 mg zoledronic acid v 44% for the placebo group; P =.127 and

250 At 3 months, 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not rec

251 ffectiveness of 5 mg intravenous infusion of zoledronic acid versus 5 mg oral risedronate for prevent

252 study was designed to compare the effects of zoledronic acid versus clodronic acid in newly diagnosed

253 fatigue (97 [14%] of 697 patients allocated zoledronic acid vs 98 [14%] of 704 allocated ibandronic

254 The zoledronic acid was administered every 3 to 4 weeks for

255 Zoledronic acid was also associated with a lower risk of

256 Zoledronic acid was also associated with a significant i

257 In patients with MAF-negative tumours, zoledronic acid was associated with higher invasive-dise

258 eatment-emergent serious adverse events, but zoledronic acid was associated with higher rates of conf

259 at randomisation with MAF-positive tumours, zoledronic acid was associated with lower invasive-disea

260 ractures more than placebo; the evidence for zoledronic acid was fair.

261 Zoledronic acid was non-inferior and superior to risedro

262 o assess whether one intravenous infusion of zoledronic acid was non-inferior to daily oral risedrona

263 The every 12 weeks regimen of zoledronic acid was noninferior to the every 4 weeks reg

264 Early zoledronic acid was not associated with increased time t

265 er and bone metastases, early treatment with zoledronic acid was not associated with lower risk for S

266 The safety profile of zoledronic acid was similar to that of placebo.

267 Proliferation induced by zoledronic acid was used as a surrogate of gammadelta TC

268 Zoledronic acid was well tolerated; the most common adve

269 In mice treated with zoledronic acid, we observed a marked inhibition of oste

270 requent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musc

271 The delayed group received zoledronic acid when lumbar spine (LS) or total hip (TH)

272 patients with cancer, who were treated with zoledronic acid, who unexpectedly developed osteonecrosi

273 The choice between pamidronate and zoledronic acid will depend on choosing between the high

274 on choosing between the higher drug cost of zoledronic acid, with its shorter, more convenient infus

275 An annual infusion of zoledronic acid within 90 days after repair of a low-tra

276 Zoledronic acid (ZA) 4 mg was administered for six 3-wee

277 Oncology [CALGB/Alliance 70604]) showed that zoledronic acid (ZA) every 3 months was noninferior to m

278 nuclear factor kappa-B ligand antibody, with zoledronic acid (ZA) for delaying or preventing skeletal

279 f clonal and primary oral keratinocytes with zoledronic acid (ZA) inhibited p63, and expression was r

280 Zoledronic acid (ZA) is commonly combined with docetaxel

281 We examined whether zoledronic acid (ZA) prevents bone loss in premenopausal

282 cal MMP inhibitor and with a bisphosphonate, zoledronic acid (ZA), revealing both to be antiangiogeni

283 ontitis (EP) in Wistar-Han rats treated with zoledronic acid (ZA).

284 containing bisphosphonates (N-BP), including zoledronic acid (ZOL) and alendronate (ALD), have been p

285 ells are expanded in vitro after exposure to zoledronic acid (ZOL) and efficiently lyse primary lymph

286 ed induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960

287 a-secretase inhibitor (gammaSI), Sirtinol or zoledronic acid (ZOL) in order to enhance the inhibitory

288 onavir + tenofovir/emtricitabine to a single zoledronic acid (ZOL) infusion (5 mg) vs placebo to dete

289 Zoledronic acid (ZOL) is a third generation bisphosphona

290 Zoledronic acid (ZOL) is an antiresorptive drug used to

291 itor (PS-341) and osteoclastic inhibition by zoledronic acid (Zol) on the development of ATLL and HHM

292 Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommende

293 Significant benefits for zoledronic acid (ZOL) over clodronate acid (CLO) were se

294 previously showed long-acting antiresorptive zoledronic acid (ZOL) prevented ART-induced bone loss th

295 Nitrogen-bisphosphonates such as zoledronic acid (ZOL) trigger selective gammadelta T cel

296 We hypothesized that the bisphosphonate drug zoledronic acid (ZOL) would inhibit tumor-induced osteol

297 To interfere with the development of SBD, zoledronic acid (Zol), a potent inhibitor of osteoclast

298 osphonate drugs, either alendronate (ALN) or zoledronic acid (ZOL), opened Cx43 hemichannels in osteo

299 Pharmacological targeting of FDPS by zoledronic acid (ZOL), which is already in clinics, exhi

300 patients with early breast cancer, adjuvant zoledronic acid (zoledronate) may reduce recurrence and